Merck & Co., Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Merck & Co., Inc. (MRK) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $260.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-24
- Merck & Co., Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $260.00M, a 28.71% increase from fiscal 2024.
- Merck & Co., Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $202.00M, a 5.61% decline from fiscal 2023.
- Merck & Co., Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $214.00M, a 82.91% increase from fiscal 2022.
- Merck & Co., Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $117.00M, a 3.54% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $260.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $202.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $214.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $117.00M 10-K · filed 2025-02-25 | $81.00M 10-K · filed 2023-02-24 |
| 2021-12-31 | $113.00M 10-K · filed 2024-02-26 | $81.00M 10-K · filed 2022-02-25 |
| 2020-12-31 | $108.00M 10-K · filed 2023-02-24 | $110.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | $116.00M 10-K · filed 2022-02-25 | $118.00M 10-K · filed 2020-02-26 |
| 2018-12-31 | $96.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $71.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $58.00M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |